|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Motives behind purchasing consortia显示文摘 | TELLA E VIROLAINEN V M | 2005 | Int J Prod Econ2005，93，： | 1 |
| 2 | TSG-Integrated Storage Platform for Early Production in the North Sea显示文摘 | Agostoni A Tella V Di Gnone E Sebastiani G | 1980 | OTC3880 OTC''121980，，： | 1 |
| 3 | Motives behind purchasing consortia显示文摘 | Tella E Virolainen V M | 2005 | International Journal of Production Economics2005，9394，： | 1 |
| 4 | The role of wages and auditing during a crackdown on corruption in the city of buenos aires显示文摘 | Di Tella R Schargrodsky E | 2003 | Journal of law and economics2003，46，1： | 1 |
| 5 | The relationship between strategic purchasing and customer satisfaction within a total quality management environment显示文摘 | Tella E | 1997 | Benchmarking: An International Journal1997，，4： | 1 |
| 6 | Reality versus Propaganda in the Formation of Beliefs about Privatization 显示文摘 | Di Tella R Galiani S Schargrodsky E | 2012 | Journal of Public Economics2012，96，5： | 1 |
| 7 | Reality versus Propaganda in the Formation of Beliefs about Privatization 显示文摘 | Di Tella R Galiani S Schargrodsky E | 2012 | Journal of Public Economics2012，96，5： | 1 |
| 8 | Chordoid meningioma: report of two cases显示文摘 | TELLA J R OSWALDO I D E HETCULAN O | 2003 | Arq Neuro Psychiatry2003，61，1： | 1 |
| 9 | Pharmacological characterizationof synthetic cannabinoid MAM-2201:radioligand binding and abuse-related effects显示文摘OBJECTIVE Over 30% of all new psychoactive substances identified by the UN Office on Drugs and Crime in 2016 were synthetic cannabinoids.The recent emergence of MAM-2201 on the illicit market is troubling because this drug has no precedent in either the scientific or patent literature,and appears to be a novel compound developed specifically as a 'graymarket' drug of abuse bystructurally combining the known synthetic cannabinoids JWH-122 and AM-2201.There is currently no published information regarding the pharmacology of MAM-2201.METHODS The present studies characterized cannabinoid-like effects of MAM-2201 in vitro(interactions with cannabinoid type 1 receptors[CB1 Rs]) and in vivo(in mice and rats).RESULTS In a radioligand binding assay using [3 H]CP55,940 in HEK cell membranes transfected with the CB1 R,MAM-2201(K i=5.4 nmol·L^(-1)),had higher binding affinity than WIN 55,212-2(K i=80 nmol·L^(-1)),and D9-THC(K i=8.3 nmol·L^(-1)).The E max values for MAM-2201 and WIN 55,212-2 in an assay of agonist inhibition of forskolin-stimulated c AMP were 85%(EC50=0.45 nmol·L^(-1)) and 95%,respectively,as compared with the D9-THC E max of 74%.In mice,MAM-2201(0.003-1.0 mg·kg^(-1),IP) produced dose-dependent cannabimimetic effects which were both more potent and more effective than those of D9-THC.MAM-2201 and D9-THC dose-dependently produced hypothermia:ED50=0.287 and 25.4 mg·kg^(-1),analgesia:ED50=0.125 and 29.4 mg·kg^(-1),and catalepsy:ED50=0.301 and18.9 mg·kg^(-1) in adult male CD1 mice.Importantly,MAM-2201 also elicited convulsant effects at a dose of 1.0 mg·kg^(-1) in 8/8 murine subjects.In rats,MAM-2201 produced dose-dependent D9-THC-like interoceptive effects in subjects trained to discriminate 3.0 mg·kg^(-1)(IP) D9-THC from saline.CONCLUSION MAM-2201 binds CB1 Rs with high affinity and agonist efficacy,and functions as a potent cannabinoid agonist in vivo across several complementary measures of cannabinoid activity in two rodent species. | William E FANTEGROSSI Aaron JANOWSKY Amy J ESHLEMAN Lauren N RUSSELL Saki FUKUDA Jyoti GOGOI Cassandra PRIOLEAU Ambuja S BALE Srihari R TELLA Merle G PAULE Takato HIRANITA | 2017 | 中国药理学与毒理学杂志2017，31，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员